Logos Global Management LP Grows Holdings in Janux Therapeutics, Inc. (NASDAQ:JANX)

Logos Global Management LP raised its position in Janux Therapeutics, Inc. (NASDAQ:JANX) by 400.0% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 750,000 shares of the company’s stock after purchasing an additional 600,000 shares during the period. Janux Therapeutics comprises about 2.5% of Logos Global Management LP’s investment portfolio, making the stock its 13th largest position. Logos Global Management LP owned about 1.45% of Janux Therapeutics worth $31,418,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Capstone Investment Advisors LLC purchased a new position in Janux Therapeutics in the 1st quarter valued at about $1,969,000. Janus Henderson Group PLC lifted its holdings in Janux Therapeutics by 1.8% in the 1st quarter. Janus Henderson Group PLC now owns 1,965,546 shares of the company’s stock valued at $73,961,000 after purchasing an additional 34,069 shares in the last quarter. Price T Rowe Associates Inc. MD purchased a new position in Janux Therapeutics in the 1st quarter valued at about $739,000. Virtu Financial LLC purchased a new position in Janux Therapeutics in the 1st quarter valued at about $609,000. Finally, Vanguard Group Inc. lifted its holdings in shares of Janux Therapeutics by 38.6% during the 1st quarter. Vanguard Group Inc. now owns 1,357,960 shares of the company’s stock worth $51,127,000 after acquiring an additional 378,477 shares during the period. 75.39% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Janux Therapeutics

In other Janux Therapeutics news, major shareholder Ventures Xi L.P. Avalon sold 2,182 shares of the stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $42.33, for a total value of $92,364.06. Following the completion of the sale, the insider now owns 7,000 shares of the company’s stock, valued at $296,310. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders sold 268,578 shares of company stock valued at $12,071,151 over the last 90 days. 35.40% of the stock is owned by corporate insiders.

Janux Therapeutics Stock Up 0.1 %

Shares of NASDAQ:JANX opened at $50.26 on Tuesday. Janux Therapeutics, Inc. has a 52-week low of $5.65 and a 52-week high of $65.60. The company has a 50 day moving average of $43.69 and a two-hundred day moving average of $44.37. The company has a market capitalization of $2.61 billion, a price-to-earnings ratio of -41.20 and a beta of 3.57.

Janux Therapeutics (NASDAQ:JANX) last issued its quarterly earnings data on Wednesday, August 7th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.31) by $0.20. Janux Therapeutics had a negative net margin of 291.17% and a negative return on equity of 8.78%. The company had revenue of $8.90 million during the quarter, compared to the consensus estimate of $0.77 million. The business’s revenue for the quarter was up 709.1% compared to the same quarter last year. On average, equities analysts anticipate that Janux Therapeutics, Inc. will post -1.18 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on JANX. Wedbush reiterated an “outperform” rating and set a $74.00 price objective on shares of Janux Therapeutics in a report on Thursday, August 8th. HC Wainwright restated a “buy” rating and issued a $63.00 price target on shares of Janux Therapeutics in a report on Monday, August 19th. Cantor Fitzgerald restated an “overweight” rating and issued a $100.00 price target on shares of Janux Therapeutics in a report on Monday, September 16th. Scotiabank cut their price target on shares of Janux Therapeutics from $47.00 to $42.00 and set a “sector perform” rating on the stock in a report on Friday, August 9th. Finally, Stifel Nicolaus initiated coverage on shares of Janux Therapeutics in a report on Friday, September 6th. They issued a “buy” rating and a $70.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat, Janux Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $66.13.

Janux Therapeutics Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.